Abstract
Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent PCV (PCV15) containing serotypes included in 13-valent PCV (PCV13) plus serotypes 22F and 33F were evaluated in infants (NCT01215188). Infants received adjuvanted PCV15, nonadjuvanted PCV15, or PCV13 at 2, 4, 6, and 12-15 months of age. Safety was monitored for 14 days after each dose. Serotype-specific IgG geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured at postdose-3, predose-4, and postdose-4. Safety profiles were comparable across vaccination groups. At postdose-3, both PCV15 formulations were non-inferior to PCV13 for 10 of 13 shared serotypes but failed non-inferiority for 3 serotypes (6A, 6B, and 19A) based on proportion of subjects achieving IgG GMC ≥0.35 µg/mL. Adjuvanted PCV15 and nonadjuvanted PCV15 were non-inferior to PCV13 for 11 and 8 shared serotypes, respectively, based on postdose 3 comparisons of GMC ratios. PCV15 induced higher antibodies to serotypes 3, 22F, and 33F than PCV13. PCV15 displayed acceptable safety profile and...Continue Reading
Citations
May 16, 2019·Journal of Medical Microbiology·Shiori SuzukiNorihisa Noguchi
Aug 2, 2019·PloS One·Mark van der LindenStephanie Perniciaro
Jul 5, 2019·Expert Opinion on Investigational Drugs·Nicola Principi, Susanna Esposito
Nov 23, 2019·Diagnostics·María Del Mar García-SuárezEnrique Santiago
Nov 15, 2019·The Pediatric Infectious Disease Journal·Jinfu XieJulie M Skinner
Jan 7, 2020·Expert Review of Vaccines·T R ConversoL C C Leite
Dec 10, 2019·The Pediatric Infectious Disease Journal·Mary CorcoranHilary Humphreys
Mar 21, 2020·Expert Review of Vaccines·Nicolas LecrenierBruce Mungall
Jun 13, 2020·Human Vaccines & Immunotherapeutics·Mehmet CeyhanYasemin Ay Altintop
May 31, 2020·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Mari ErikssonVeli-Jukka Anttila
Jul 9, 2020·The Pediatric Infectious Disease Journal·Heather L PlattUNKNOWN V114-008 Study Group
Dec 7, 2018·BMC Infectious Diseases·Joon Young SongWoo Joo Kim
Apr 28, 2020·Clinical and Experimental Pediatrics·Jin Lee
May 16, 2020·F1000Research·Charles Feldman, Ronald Anderson
Jan 29, 2019·Human Vaccines & Immunotherapeutics·R RuppL Musey
Mar 17, 2020·Frontiers in Microbiology·Julio SempereMirian Domenech
Apr 8, 2020·AIMS Public Health·Godwin Oligbu
Jan 17, 2019·Human Vaccines & Immunotherapeutics·Helen L StaceyLuwy K Musey
Mar 21, 2020·Vaccines·Malihe MasomianChit Laa Poh
Oct 22, 2020·Journal of Medical Economics·Tianyan HuTanaz Petigara
Nov 2, 2019·Infectious Disease Clinics of North America·Deirdre Fitzgerald, Grant W Waterer
Feb 3, 2020·International Journal of Pediatric Otorhinolaryngology·Regie Lyn P Santos-CortezGarth D Ehrlich
Mar 16, 2021·Vaccine·Zahin Amin-ChowdhuryShamez N Ladhani
Apr 5, 2021·Vaccine·Mari ErikssonVeli-Jukka Anttila
Apr 26, 2021·Infectious Diseases and Therapy·Amgad GamilAngelica M Claveria
May 26, 2021·Pneumonia·Alex J J ListerStuart C Clarke
Jun 3, 2021·Vaccine·Debra McGuinnessJulie M Skinner
Jun 22, 2021·American Journal of Preventive Medicine·Kenneth J SmithRichard K Zimmerman
Jul 1, 2021·Diagnostic Microbiology and Infectious Disease·Alyssa R GoldenUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)
Jul 19, 2021·Microbial Pathogenesis·Lazara Elena Santiesteban-LoresEneas Carvalho
Aug 27, 2021·Human Vaccines & Immunotherapeutics·Eiman MokaddasM John Albert
Sep 1, 2021·Journal of Medical Economics·Tianyan HuTanaz Petigara
Aug 30, 2021·Vaccine·Alyssa R GoldenUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)
Apr 21, 2020·Infectious Disorders Drug Targets·Abdollah KarimiSedigheh Rafiei Tabatabaei
Dec 10, 2021·Expert Review of Vaccines·Bruce A MungallLamine Soumahoro